Completed PHASE4 INTERVENTIONAL 5-arm NCT00420927

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis (OPTIMA)

A Multicenter, Randomized, Double-Period, Double - Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis (OPTIMA)

Sponsor: Abbott

Conditions Rheumatoid Arthritis

Interventions adalimumab methotrexate placebo

Updated 7 times since 2017 Last updated: Apr 16, 2012 Started: Dec 31, 2006 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Rheumatoid Arthritis and is currently completed. Abbott leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Sep 2020 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Sep 2020 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aguascallentes, Mexico , Albuquerque, United States , Amiens, France , Arnhem, Netherlands , Auckland, New Zealand , Aventura, United States , Bad Nauheim, Germany , Bath, United Kingdom , Bend, United States and 139 more locations